The content of this paper has not been published or submitted for publication elsewhere. All authors have contributed significantly to this paper and are in agreement with its content. The authors have received no financial support related to this paper and have no relationships that may lead to a conflict of interest.
Quetiapine XR-induced neutropenia: is a clozapine trial still possible for treatment-resistant schizophrenia? A case report
Article first published online: 1 APR 2014
© 2014 Wiley Publishing Asia Pty Ltd
Early Intervention in Psychiatry
Volume 9, Issue 2, pages 151–155, April 2015
How to Cite
Crépeau-Gendron, G. and L'Heureux, S. (2015), Quetiapine XR-induced neutropenia: is a clozapine trial still possible for treatment-resistant schizophrenia? A case report. Early Intervention in Psychiatry, 9: 151–155. doi: 10.1111/eip.12134
- Issue published online: 11 MAR 2015
- Article first published online: 1 APR 2014
- Manuscript Accepted: 5 FEB 2014
- Manuscript Received: 7 OCT 2013
- antipsychotic agent;
Our case report addresses the use of clozapine in patients who have a history of quetiapine XR-induced neutropenia. There are no current guidelines for this situation.
We present the case of a young woman treated with clozapine at a first-episode psychosis clinic after a moderate quetiapine XR-induced neutropenia (0,5–1,0 × 109 L−1).
The patient was successfully treated with clozapine and lithium, with less psychotic symptoms and a better level of functioning. The neutrophil count remained normal during the treatment period, which has been longer than a year.
The outcome of this case supports the notion that clinicians could consider introducing clozapine in treatment-refractory patients who have a history of quetiapine XR-induced neutropenia, with close blood monitoring. Lithium co-administration may play a role in maintaining a normal neutrophil count.